Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
2 Top Biotech Stocks to Buy in August
09:15am, Sunday, 06'th Aug 2023
Vertex's business should get a major boost in the coming years with new approvals. Eli Lilly's expanding portfolio of new products will help it maintain its recent momentum.
Eli Lilly reports positive results in trial of tretment for non-small cell lung cancer
08:01am, Friday, 04'th Aug 2023
Eli Lilly & Co. LLY, -1.17% said Friday a late-stage trial of a treatment for a type of non-small cell lung cancer met its main goal. The Phase 3 trial dubbed Libretto-431 showed a statistically signi
Beat the Dow Jones With This Unstoppable Dividend Stock
07:45am, Friday, 04'th Aug 2023
Eli Lilly's current portfolio looks competitive when excluding its covid products. The company's pipeline of potential products is highly promising, too.
The issue with Eli Lilly is the very competitive drug market, says Short Hills Partners' Weiss
02:17pm, Wednesday, 02'nd Aug 2023
CNBC's 'Halftime Report' Investment Committee discusses Eli Lilly's current valuation relative to revenue growth, and the obesity drug market.
Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen
07:45am, Monday, 31'st Jul 2023
Biogen and Eli Lilly are two major competitors in the field of Alzheimer's disease. Eli Lilly's medicine appears to slow the rate of cognitive decline more than Biogen's.
AI Stock Marvell And Eli Lilly Lead 5 Names Near Buy Points As S&P 500 Rallies On
11:12am, Saturday, 29'th Jul 2023
Top AI stock Marvell Technology and Eli Lilly lead this weekend's watch list of five stocks near buy points as the new S&P 500 bull market revs back up.
2 Healthcare Stocks That Could Make You Richer
09:30am, Saturday, 29'th Jul 2023
As a producer of medicines for animals, Zoetis benefits from increased spending on pets. Thanks to a strong product line, Eli Lilly briefly ranked as the biggest pharma company this year.
Eli Lilly: There Is No Logic To This Over Optimism
04:00pm, Friday, 28'th Jul 2023
Mounjaro may rake in $25B of annualized sales by 2026, exceeding ABBV's Humira. This naturally explains Mr. Market's optimism surrounding the LLY's stock thus far. The same has been witnessed with NVO
Eli Lilly Says Weight-Loss Drug Helps Patients Lose 26% of Their Weight, More Than Rivals
05:50pm, Thursday, 27'th Jul 2023
Eli Lilly said that two Phase 3 trials of its weight-loss drug tirzepatide showed patients lost 26.6% of their body weight on average, more than competitors.
7 Millionaire-Maker Healthcare Stocks to Buy Before the Window Closes
09:42am, Thursday, 27'th Jul 2023
Healthcare continues to be a major industry and economic driver around the world. According to the American Medical Association, spending on healthcare in the U.S. totals more than $4 trillion each ye
Eli Lilly vs. Novo Nordisk: What's the Better Weight-Loss Stock to Buy?
08:15am, Thursday, 27'th Jul 2023
Eli Lilly has a couple of promising weight-loss treatments that could gain approval in the near future. Novo Nordisk's obesity care revenue doubled in the first quarter -- and stands to go still highe
3 Risky Stocks to Avoid at All Costs in 2023
02:26pm, Wednesday, 26'th Jul 2023
It's no secret that a few names have reached excessive valuations during the recent growth stocks rally. And so, they are overdue for a correction.
Is Eli Lilly Stock Still a Top-Growth Play?
02:40pm, Tuesday, 25'th Jul 2023
Eli Lilly has been a top performer over the past three years. Future appreciation will depend on how the competitive landscape in weight loss evolves.
Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush
08:46am, Monday, 24'th Jul 2023
Shares of Eli Lilly & Co. NYSE: LLY closed 2.80% higher for the week ended July 21, a week after Lilly said it would buy Versanis, a privately held clinical-stage biopharmaceutical company focused on
Lilly Joins Biogen as Alzheimer's Drugs Finally Emerge
08:03pm, Friday, 21'st Jul 2023
In trials, Biogen and Eli Lilly have shown that their drugs can slow early-stage decline in the disease. It could be a bonanza for patients—and investors.
